Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA-guided adjuvant therapy after SBRT in early lung cancer
NCT05411809Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Randomised, open-label trial in non-small cell lung cancer (NSCLC), sponsored by Peking University Third Hospital. Planned start Jun 2022; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05411809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411809.